论文部分内容阅读
阿糖胞苷(Ara-C)是治疗急性非淋巴细胞白血病(ANLL)的主要药物之一。常规量100～200mg/m~2单一治疗的完全缓解率(CR)14～25％,联合治疗的CR60～80％,但两年内复发率至少80％,即使应用最新的药物治疗,再次CR仅25～31％,且持续时间短暂。临床上通常把复发的和对常规方案治疗无效的病例称为难治性ANLL,对此,医生们常常束手无策。1974年,Momporlar首次用大剂量Ara-C治疗一例晚期ANLL,1979年后被广泛用于治疗ANLL,急淋白血病、恶性淋巴瘤、慢粒白血病加速
Cytarabine (Ara-C) is one of the main drugs for the treatment of acute non-lymphocytic leukemia (ANLL). Conventional doses of 100-200mg / m 2 single treatment complete remission rate (CR) 14 ~ 25%, combined treatment of CR 60 ~ 80%, but within two years the recurrence rate of at least 80%, even with the latest drug treatment, CR again only 25 ~ 31%, and the duration is short. Clinically, relapsed and ineffective regimens are often referred to as refractory ANLLs, and doctors are often overwhelmed. In 1974, Momporlar was the first to treat a late ANLL with high-dose Ara-C and was widely used to treat ANLL, acute leukemia, malignant lymphoma, and accelerated leukemia after 1979